Seal.

Also headquartered in Fort Worth, DFB provides technology-driven products,
outsourcing services, and licensing opportunities to the healthcare
industry worldwide through its affiliate companies, contract partners , and
branded marketing organizations.

CytoGenix First Quarter 2005 Update

J.
CytoGenix , Inc. Phanuel withdrew from
the China agreement. The results from
the analysis of the Rambazole treated skin compared to vehicle treated skin
showed strong dose dependent activity with changes of 10 to 1000 fold for
these biological markers as compared to baseline, whereas virtually no
changes were seen in the vehicle treated skin."

Dr.9% for slowing the growth
of unwanted facial hair in women. For a discussion of
these and other risks and uncertainties that may effect the forward -looking
statements please see the risk factors in our Quarterly Report on Form 10Q,
which is on file with the Securities and Exchange Commission.

scaring imitates

An Alcohol-based, Zinc Pyrithione
(ZPT)-preserved product can provide the strategic defense needed to assist
in reducing the number of post-surgery biofilm infections that proliferate
in hospitals across the United States, according to research findings
published as an abstract and presented at the international meeting of the
Association for Professionals in Infection Control and Epidemiology (APIC)
conference in Baltimore, MD, June 19-23.M. The Company believes the suit is
without merit.S. The
analysts are responsible only to the public. Reasonable appraisers
can differ in their assumptions and, therefore, in their estimates of
value. Methodologically, our valuation approach is sound and commonly
accepted in the finance community and by pharma executives.

blackheads peroxide

The combined market for topical
dermatologic products treating the target inflammatory conditions such
as psoriasis, atopic dermatitis, bed sores and acne is in excess of
$10BN annually. ("AVGI"), a party in interest as a sublicense of Waldroff's,
counterclaimed for damages, attorney's fees, unrelated torts, and a
permanent injunction to honor the purported licenses. In
Barrier's recently completed Phase 2a trial with its oral formulation of
Rambazole , 17 subjects with moderate-to-severe acne were treated with 1 mg
of oral Rambazole once daily for 12 consecutive weeks.

About Rambazole

Rambazole is Barrier's second product candidate based on the Retinoic Acid
Metabolism Blocking Agent (RAMBA) class of molecules.
European Phase 2a studies in psoriasis and acne have been completed for the
oral dose form of the drug and Barrier is planning a Phase 2b trial with
oral Ramabazole in psoriasis.

antiseptic irritation

presence in
the research, development , and marketing of branded pharmaceuticals, over
the counter drugs, and medical devices for surgical , dermatology, and
tissue management indications.OB)

Valued shareholders:

CytoGenix is poised for the achievement of significant milestones
in the coming fiscal year.

Bioscience Valuation (BSV GmbH) Report

Bioscience Valuation (BSV) is a management consulting firm located
in Grainau, Germany specializing in the evaluation of pharmaceutical
R+D projects, portfolios , and platform technologies.
The Company continues to be aggressive in the protection of its
proprietary technology capitalizing on the addition of second in-house
intellectual property counsel. Waldroff ., J. Additional information about
CytoGenix and its technology can be found on the website at
www . In addition, none of the
volunteers had signs of irritation after application of topical Rambazole
or its vehicle.

Acne is tough zits! Some zit sites will be appropriate, but ACNE treatment will be most preferred.

scaring hydrate

and Lawton
Seal, PhD of HEALTHPOINT compared the use of HEALTHPOINT's Alcohol -based,
ZPT-preserved product, ACTIPREP, against both the biofilm and planktonic
forms of Staphylococcus . An aggressive research and development
effort has brought HEALTHPOINT's unique technologies to the market, setting
the pace for its highly trained field sales organization of direct sales
representatives . With continued discoveries in research,
aggressive protection of proprietary technology, success in product
development, and anticipation of revenues from synthetic DNA sales,
this year promises to be an exciting year for the shareholders of
CytoGenix.g.
Synthetic DNA offers several competitive advantages over the current
practice of using bacterial fermentation to produce commercial
quantities of clinical grade DNA.
President + Chief Executive Officer

About CytoGenix: CytoGenix, Inc . Dutton + Associates,
LLC, does not accept payment of any of its fees in company stock or
any form of securities, as receipt and disposal of these securities
under these alternative payment methods might compromise the integrity
of the continuing research program.07% concentration or a
0. Skin biopsies were taken and analyzed
for three key biological markers that are known signals for potential
therapeutic effect when topical retinoids are applied.barriertherapeutics.

imitates reversion

"

The Alcohol-based formulation preserved with ZPT is the basis of
HEALTHPOINT's patented Trizenol technology used in the company's
preoperative patient skin preparation system products included in the
study.

HEALTHPOINT will have more information about the study and Actiprep during
APIC at booth number 624.)

CytoGenix filed a Declaratory Judgment action in March 2004 to
obtain a finding of non -liability with respect to two license
agreements, one for shrimp and one for horses, purportedly issued in
1998 to William B.

Barrier also conducted a double-blind, vehicle controlled study with its
topical formulation of Rambazole in which each of 15 healthy volunteers
were treated for 9 days with both the drug at a 0. Barrier undertakes no obligation to update publicly
any forward -looking statement.

peroxide scaring

Prevention
is key, especially when dealing with such resistant infections. We are pleased to offer a way for doctors and their
staffs to reduce these surgical site biofilm infections . The Company commissioned these reports and provided
data and response to the analyst's questions; however, the analyst's
conclusions were independently constructed. Most standards emphasize accounting
figures that are not appropriate to value R+D projects.
Barrier Therapeutics, Inc. The levels of biomarkers
obtained with the 0. Cauwenbergh is scheduled to present this data as part of an update to
the investment community at Barrier's 1st Analyst and Investor Day on
September 20th, 2005 .01%) Topical Solution in the U. Barrier has product
candidates in earlier stages of clinical development for the treatment of
acne, psoriasis and fungal infections.

irritation scaring

"The Alcohol-based, ZPT-preserved formula achieved a 50 percent reduction
of the biofilm within 15 seconds and a complete kill of the
biofilm-protected bacteria in two minutes or less," reports Dr. The technology has proved effective
for healthcare professionals preparing both their patients and themselves
for hundreds of thousands of surgical procedures performed every week. We are expanding the application of our
highly innovative technology.
Bioscience Valuation's analysis indicates that CytoGenix is
currently significantly undervalued and therefore represents a good
opportunity for both existing and prospective shareholders . Dutton and Associates, LLC

Dutton + Associates is an investment research firm offering
high -quality, independent, fundamental research on small cap public
companies. Both Waldroff and AVGI
also sued three Directors of CytoGenix for interfering with the
licenses. Dutton + Associates provides continuing analyst coverage
of over 85 enrolled companies, and its research, estimates, and
ratings are carried in all the major databases serving institutions
and online investors.

35% concentration and its vehicle.

cleanser pores

, a DFB company, is represented by a group of products
based on the topical antimicrobial Alcohol, preserved with ZPT.

HEALTHPOINT

Researchers Daryl Paulson, PhD of BioScience Laboratories , Inc. affiliate company. Work to be outsourced includes manufacturing of
drug substance, formulation of drug product as well as conduct of
preclinical safety and biodistribution studies. CY303 will be tested
in several established models in an academic setting to clarify the
activity, potency and duration of action prior to the initiation of
preclinical animal testing. The synDNA(TM) technology is particularly well suited
for the production of DNA vaccines. Development of DNA vaccines is a
major component of the Company's strategic plan.

Legal Issues

Waldroff/AVGI

(William B. Waldroff and Applied Veterinary Genomics, Inc. The court has preliminarily entered a judgment ordering
CytoGenix to perform according to the licenses and for attorney's
fees. CytoGenix is prepared to comply with the judge's order to
provide product at cost plus twenty percent (20%).

Phanuel Pursuits

Phanuel Pursuits, Ltd. Phanuel owes unpaid option fees under the Indian
option agreement including a specific payment required to purchase the
Company's data needed for submission to the Indian regulatory
authorities. patent and over 44 international or U. Although any
party can pay the enrollment fee, reports are performed on behalf of
the members of the public, and are not a service to any company. Users of this report should be aware that the projected
future cash flows may or may not materialize. CytoGenix
paid BSV $45,000 for these services. These
factors include, but are not limited to, general economic conditions,
risks associated with the acceptance of new products, competition, and
other factors more fully detailed in the company's filings with the
Securities and Exchange Commission.35% concentration of the topical Rambazole formulation
are equivalent to those reported in the literature for currently marketed
concentrations of topical retinoic acid. is a pharmaceutical company focused on the
discovery, development and commercialization of pharmaceutical products in
the field of dermatology. Given these
risks and uncertainties, any or all of these forward-looking statements may
prove to be incorrect.

ddf blackheads

When bacteria gather and attach to damaged tissue or an inanimate surface
-- such as medical implants like prosthetic joint replacements or catheters
-- resulting biofilm infections are from 500 to 1,500 times more resistant
to standard antibiotic therapy than so-called free-floating, planktonic
bacterial infections .S. v. The Company is headquartered in
Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium
and Ontario, Canada.

inhibiting pattingham

The
forecast models project significant year-by-year growth with an
estimated net present value of $1.
Their continuing year-long program of research coverage allows
under-followed companies to gain a thorough, independent analysis of
their competitive position along with independently developed earnings
and valuation models. Waldroff and Applied Veterinary Genomics,
Inc. The company has developed a breakthrough synthetic process
for large-scale production of high purity DNA at fraction of the cost
of traditional fermentation methods. CytoGenix currently has one
issued U.S. The valuation is not in compliance with U. Barrier has eight product candidates in
various stages of clinical development.

reversion cleanser

The BSV report
indicates that the herpes treatment market is $2-3BN annually and this
remains a conservative estimate due to the underreporting of the
condition. CY403 targets a different gene than CY401 and will be
developed for use in the treatment of the most serious unmet medical
need in bacterial infectious disease, e.
SAFE HARBOR: Except for statements of historical fact, the
statements in this press release are forward-looking.

PRESS RELEASE Barrier Therapeutics Reports Positive Phase 2a Data for Oral Rambazole(TM) in Moderate to Severe Acne

Rambazole is a novel retinoic acid metabolism-blocking agent (RAMBA). There were no serious treatment-related adverse effects
reported. Studies to date
suggest that Rambazole is more selective and more active than Barrier's
first generation RAMBA-based product candidate.

pores tretinoin

M.
About Biosciences Valuations GmbH: BSV is a firm of well respected
financial valuation consultant based in Germany, with emphasis on
performing valuations for the biopharmaceutical industry on drug
products that are in stages of development.
Revenue Ruling 59-60, nor does it comply with standards set forth by
the ASA, IBA, NACVA and AICPA.

"These positive Phase 2a results indicate that oral Rambazole is active in
moderate to severe inflammatory acne, and that depending on the outcome of
future , full scale clinical trials, this drug may one day fill the need for
safe and effective oral treatments for moderate and severe acne. These
results further build on our previously announced promising clinical data
for oral Rambazole for psoriasis," stated Geert Cauwenbergh, Ph. and Canada for
the treatment of solar lentigines, a common condition also known as "age
spots," and recently obtained the Canadian distribution rights for
Vaniqa (eflornithine hydrochloride) Cream 13.

zits pores

PRESS RELEASE HEALTHPOINT (R) Alcohol-Based ZPT-Preserved Surgical Prep Products Can Prevent Dangerous Biofilm Infections

Product Development Update

CY301 (SIMPLIVIR(TM)) for topical herpes simplex infection

Since our pre Investigational New Drug (IND) meeting with Federal
Drug Administration (FDA ), we have identified several vendors capable
of conducting the required work packages necessary to allow filing of
an IND application., multi-drug resistant
staphylococcus aureus infections. We have
evaluated multinational suppliers for the raw materials necessary for
our process and we are currently negotiating pricing to assure a
competitive cost of goods for our finished drug substance . Dutton + Associates, LLC,
one-year continuing research program is U. All electronic reports and
distribution are included in the initial research fee. J. All major cash flow risks have been
explicitly modeled.D.com for up to 90 days.

Web site: http://www.

Acne treatment sites will fit in best here .

peroxide tretinoin

The independent study, Surgical Preps and Biofilms, reviewed vascular
catheterization, a medical procedure performed 20 million times each year
in the United States to see how the Alcohol -based, ZPT-preserved formula
can prevent the formation of biofilm infections. "The
Alcohol-based , ZPT-preserved formula achieved a complete kill of the
planktonic bacteria within 15 seconds.

The product line is also utilized extensively across the United States.D. pending patent
applications claiming methods and materials in connection with this
platform technology.M. The Company is developing
an oral formulation of Rambazole for the treatment of psoriasis and severe
acne, as well as a topical formulation for psoriasis, acne, and wrinkles.

unclog blemishes

5BN by 2008. Dutton rates CytoGenix as a
Speculative Buy with a twelve month target price of $0. The Centers for Disease Control and the World
Health Organization have identified multi-drug resistant bacterial
infections as a serious emerging threat to the general public. These advantages include reduced
cost, higher purity, faster production cycle times.
A jury trial was held in February 2005. The results of this
study indicate that 16 of 17 subjects (94%) experienced a reduction in
total acne lesion count of more than 50% and 6 of 17 subjects (35%) were
considered "cleared or almost cleared." To be considered "cleared or
almost cleared" a subject must have had more than 90% reduction in total
lesion count.

pattingham unclog

Since its inception in 1992, HEALTHPOINT has established a U.

Business Editors/Health/Medical Writers/Biotech Writers/Health
Editors
BIOWIRE2K

HOUSTON----CytoGenix, Inc. Phanuel filed suit October 8, 2004 alleging that the
Company had withheld the data and stopped work on herpes product
development .S.
The cost of enrollment in the J. R+D projects,
however, are the main source of value for biotech companies. Such statements
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from the statements made.

Safe Harbor Statement

In addition to historical facts or statements of current condition, this
press release contains forward-looking statements within the meaning of the
"Safe Harbor" provisions of The Private Securities Litigation Reform Act of
1995, including statements regarding the future development of Rambazole,
the potential safety and efficacy of Rambazole, if approved, and the
commencement of future clinical trials. Forward -looking statements provide
Barrier's current expectations or forecasts of future events. Barrier 's
performance and financial results could differ materially from those
reflected in these forward -looking statements due to the outcome of future
clinical trials, the decisions of regulatory authorities , general
financial, economic, regulatory and political conditions affecting the
biotechnology and pharmaceutical industries generally.

keratosis irritation

The preventative protocol, a technology developed and marketed by
HEALTHPOINT, Ltd. The Dutton report concludes that, at current
levels, CytoGenix remains an unexploited, virtually undiscovered
company with exciting new technology. Both charges are false.

Very truly yours,

Malcolm Skolnick, Ph.S. The four most advanced product
candidates include one for the treatment of diaper dermatitis complicated
by candidiasis, which is under FDA review, and three products, which are in
or entering Phase 3 clinical trials for the treatment of seborrheic
dermatitis, onychomycosis, and congenital ichthyosis.

pores blemishes

(OTCBB:CYGX.

CY403 for blood-borne Staphylococcus infection

Following on the success in laboratory and animal studies of
CY401, a novel drug product, CY403 was added to the company's
pipeline.

CY303 for topical skin inflammation

The Company's product for topical inflammation, CY302, was renamed
CY303 to conform to a standard nomenclature system recently
implemented to maintain control of the expanding number of new
products being developed by our Research group.

synDNA(TM) process for cell -free DNA production

We are building a commercial scale manufacturing facility to
produce mini -circle DNA for our future clinical development needs.
An industry leading engineering firm has been engaged and is
currently conducting the preliminary design feasibility study. We have
begun laying the framework for a Quality Assurance plan that will
provide the infrastructure to maintain compliance with current Good
Manufacturing Procedures (cGMP) necessary for FDA certification., entered into an option agreement with the
Company to obtain licenses to commercialize the Company's anti-herpes
product in Peoples Republic of China and India.D. (NASDAQ: BTRX), a
pharmaceutical company developing and commercializing products in the field
of dermatology, today reported positive Phase 2a data for its oral
formulation of Rambazole in the treatment of moderate to severe acne
and positive biological activity data for its topical formulation of
Rambazole. The Company currently markets Solag
(mequinol 2%, tretinoin 0.

dissolves peroxide

Analyst Reports

The following evaluations of the Company were performed by two
independent firms. is a Houston-based
biopharmaceutical company that develops and markets innovative
products and services based on its proprietary ssDNA expression
technology . The company is additionally
responsible for additional pass through costs, including printing,
estimated at $3,250 for the year.
The valuation is derived from projected cash flows and relies on
information provided by CytoGenix' management, supported by our own
research. Inflammatory and non-inflammatory lesions responded equally
well to treatment. Dr.

cleanser antiseptic

Such persistent, preventative killing-power is known as cumulative
effect, a major benefit of ZPT. "This reconfirms previous studies that
have proved the persistence and effectiveness of Alcohol-based,
ZPT-preserved products. The product line includes TRISEPTIN Hand and Body Antiseptic and
ACTIPREP One-Step Preoperative Prep. We have advanced this product from
target identification to preclinical testing in less than three months
and this efficiency is indicative of our ability to expedite the early
drug discovery process.
CytoGenix antimicrobial products address this serious unmet medical
need which the government accounting office (GAO) estimates the cost
of antibiotic resistance is approximately $5BN annually.
We are inceasing the range and scope of this application with further
filings based on new developments and improvements made in the last
quarter. Its 29
senior analysts are primarily CFAs, and have expertise in many
industries.S. $33,000 prepaid before
commencement of its research activities.,
Chairman and Chief Executive Officer of Barrier Therapeutics, Inc.com.

unclog cleanser

In the past, nearly all
vascular catheterizations became infected with biofilms frequently caused
by the bacteria Staphylococcus epidermidis, commonly known as a Staph
infection."

According to the doctors' research findings, applying an Alcohol -based,
ZPT-preserved topical antimicrobial to a site two minutes prior to a
medical procedure will not only kill both planktonic and biofilm
Staphylococcus epidermidis already present on the skin, but it will also
prevent the rebound of skin colonization, which further protects the
patient . HEALTHPOINT is based in Fort
Worth, Texas. BSV uses advanced
financial modeling based on thorough market and risk analysis to
develop R+D strategies that reduce risk and enhance the value of your
projects.90 a share. We expect these
IND-enabling studies to be completed this year.

Valuation Approach:

The valuation is based on a Monte Carlo simulation of future
expected net cash flows . Cauwenbergh's presentation will be available
live via a webcast and will be archived and accessible through the
Company's website at www.

sterolithography keratosis

"The findings are very encouraging," said Steve Owens , Director of
Marketing HEALTHPOINT Surgical. Visit HEALTHPOINT's web site at www. The jury did not assess any damages against any of the
Directors or against CytoGenix and dismissed Waldroff and AVGI 's
counterclaims.cytogenix.com

"In
addition, the biomarker findings with topical Rambazole may also open the
therapeutic door to an effective and non-irritating alternative to the
widely used topical retinoic acid products and their derivatives for
dermatological indications such as acne and photo-damage.

Barrier Therapeutics, Inc.S.

cutaneous cleanser

Fortunately for doctors, patients , and the healthcare industry, these
inherently difficult-to-treat multilayered communities of bacteria are now
being successfully challenged by a new, preventative topical antimicrobial
protocol for biofilms, making it much harder for them to do their damage.
ACTIPREP is used by staff in the operating room to prepare the patient's
surgical site.

SURG-060205

We
expect to complete construction of a facility capable of supplying our
internal need for DNA as well as selling the extra capacity the
general market.

Intellectual Property

In December of 2004, the Company submitted a new United States
Patent Application for the method to produce therapeutic quality DNA .
About Dutton + Associates: Dutton + Associates is one of the
largest independent investment research firms in the U.barriertherapeutics.

Some sites will offer specific acne treatment products, some will have specific acne treatment methods, some will have both and more.

chamomile cutaneous

HEALTHPOINT, with over 300 employees , is a DFB
Pharmaceuticals, Inc.healthpoint.com. Non-serious side effects experienced by this patient group
included some dryness of skin and lips.

About Barrier Therapeutics, Inc.